WO2004087011A2 - Therapeutic agent delivery device with controlled therapeutic agent release rates - Google Patents
Therapeutic agent delivery device with controlled therapeutic agent release rates Download PDFInfo
- Publication number
- WO2004087011A2 WO2004087011A2 PCT/US2004/009652 US2004009652W WO2004087011A2 WO 2004087011 A2 WO2004087011 A2 WO 2004087011A2 US 2004009652 W US2004009652 W US 2004009652W WO 2004087011 A2 WO2004087011 A2 WO 2004087011A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agent
- medical device
- implantable medical
- layer
- poly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
- A61F2002/91541—Adjacent bands are arranged out of phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/92—Method or apparatus for preparing or treating prosthetic
Definitions
- the invention relates to a therapeutic agent delivery device which comprises a gradient of therapeutic agent within mixing layers which provides for the controlled release of water soluble therapeutic agents.
- Known construction materials for use in stents include polymers, organic fabrics and biocompatible metals, such as stainless steel, gold, silver, tantalum, titanium, and shape memory alloys, such as Nitinol.
- Restenosis is a major complication that can arise following vascular interventions such as angioplasty and the implantation of stents. Simply defined, restenosis is a wound healing process that reduces the vessel lumen diameter by extracellular matrix deposition, neointimal hyperplasia, and vascular smooth muscle cell proliferation, and which may ultimately result in renarrowing or even reocclusion of the lumen.
- the fixed matrix polymer carriers frequently used in the device coatings typically retain approximately 30% of the beneficial agent in the coating indefinitely. Since these beneficial agents are frequently highly cytotoxic, sub-acute and chronic problems such as chronic inflammation, late thrombosis, and late or incomplete healing of the vessel wall may occur. Additionally, the carrier polymers themselves are often highly inflammatory to the tissue of the vessel wall. On the other hand, use of biodegradable polymer carriers on stent surfaces can result in the creation of "virtual spaces" or voids between the stent and tissue of the vessel wall after the polymer carrier has degraded, which permits differential motion between the stent and adjacent tissue. Resulting problems include micro-abrasion and inflammation, stent drift, and failure to re-endothelialize the vessel wall.
- the liquefied therapeutic agent layer comprises from about 20% to about 95% therapeutic agent and from about 5% to about 70% pharmaceutically acceptable polymer preferably from about 50% to about 95% therapeutic agent and from about 5% to about 50% pharmaceutically acceptable polymer, more preferably from about 50% to about 60% therapeutic agent and from about 40% to about 50% pharmaceutically acceptable polymer.
- the therapeutic agent is preferably antithrombotic agents, a antineoplastic agent, a neoplastic agent, an antiproliferative agent, an antisense compound, an immunosuppresant, an angiogenic agent, an angiogenic factor, an antiangiogenic agent, or an anti-inflammatory agent, or combinations thereof. More preferably the therapeutic agent is of 2-chlorodeoxyadenosine, bivaliradin, Resten NG, or an oliogonucleotide, or mixtures thereof.
- the present invention relates to a delivery device for delivery of water soluble therapeutic agents to a patient. More particularly, the invention relates to a medical device having therapeutic agents protected from premature release into a patient by one or more mixing layers. Details for the device design, therapeutic agents, therapeutic agent layers, and mixing layers may also be found in U.S. patent application serial number 10/253,020, filed on September 23, 2002, incorporated herein by reference in its entirety. First, the following terms, as used herein, shall have the following meanings: [0029]
- the term "beneficial agent” as used herein are intended to have their broadest possible interpretation and is used to include any therapeutic agent or drug, as well as inactive agents such as barrier layers, carrier layers, therapeutic layers or mixing layers.
- the term "mixing layer” refers to a matrix layer which is adjacent a therapeutic agent layer. Before the mixing layer is introduced to the device, the mixing layer preferably contains no therapeutic agent, or it contains a therapeutic agent which is different from the therapeutic agent of the therapeutic agent layer.
- the mixing layer is introduced in a liquified state and may mix with the therapeutic agent layer causing the mixing layer to incorporate a portion of the adjacent therapeutic agent layer once the layer has at least partially solidified.
- the mixing layer may also serve to control the rate at which a drag is released into the reaction environment. The release rate can be controlled by the rate of erosion or dissolution of the mixing layer or by the rate of diffusion of the therapeutic agent from within the mixing and therapeutic agent layers.
- the mixing layer is preferably bioresorbable.
- lipid refers to a matrix that comprises preferably non-polymeric small organic, synthetic or naturally-occurring, compounds which are generally amphipathic and biocompatible.
- the lipids typically comprise a hydrophilic component and a hydrophobic component.
- Exemplary lipids include, for example, fatty acids, fatty acid esters, neutral fats, phospholipids, glycolipids, aliphatic alcohols, waxes, terpenes, steroids and surfactants.
- Term lipid is also meant to include derivatives of lipids.
- additives refers to pharmaceutically acceptable compounds, materials, and compositions that may be included in a matrix along with a therapeutic agent.
- An additive may be encapsulated in or on or around a matrix. It may be homogeneously or heterogeneously disposed, as defined herein, in the matrix.
- Some examples of additives are pharmaceutically acceptable excipients, adjuvants, carriers, antioxidanls, preservatives, buffers, antacids, and the like, such as those disclosed in Remington: The Science and Practice of Pharmacy, Gennaro, ed., Mack Publishing Co., Easton, Pa., 19th ed., 1995.
- heterogeneously disposed or “heterogeneously dispersed” refers to a mixture in which the components are not mixed uniformly into a matrix.
- solid solution refers to a homogeneously dispersed mixture of two or more substances. A component that is mixed uniformly in a matrix in such a manner that the component is macroscopically indistinguishable from the matrix itself.
- a solid solution is a metal alloy, such as brass.
- multi-phase mixture refers to a mixture of two or more substances in which at least one component is macroscopically distinguishable from the matrix itself.
- An example of a multi-phase mixture is a macro emulsion.
- agents such as, for example, protein drags, enzymes, antibodies, antisense oligonucleotides, ribozymes, gene/vector constructs, and cells (including but not limited to cultures of a patient's own endothelial cells).
- Many of these types of agents are biodegradable or fragile, have a very short or no shelf life, must be prepared at the time of use, or cannot be pre-loaded into delivery devices such as stents during the manufacture thereof for some other reason.
- the large holes 20 in the expandable device of the present invention form protected areas or receptors to facilitate the loading of such an agent either at the time of use or prior to use, and to protect the agent from abrasion and extrusion during delivery and implantation.
- the volume of beneficial agent that can be delivered using holes 20 is about 3 to 10 times greater than the volume of a 5 micron coating covering a stent with the same stent/ vessel wall coverage ratio. This much larger beneficial agent capacity provides several advantages. The larger capacity can be used to deliver multi-drag combinations, each with independent release profiles, for improved efficacy.
- the openings have an area of at least 5 x 10 "6 square inches, and preferably at least 7 x 10 "6 square inches.
- the time period for delivery can be modulated from minutes, to hours, to days. Preferably the time period for delivery is greater than 1 day, more preferably greater than 3 days.
- the layers are loaded into the medical device by first loading the therapeutic agent layer, 40, into the holes of the medical device in a liquefied state. The therapeutic agent layer is then allowed to solidify. A first mixing layer, 50, is then loaded into the holes within the medical device in a liquefied state. When the liquid mixing layer, 50, comes into contact with the therapeutic agent layer, 40, a portion of the therapeutic agent layer is liquefied allowing a co-mingling of some of the components of each of the two layers. When the mixing layer solidifies, there is therapeutic agent within the mixing layer.
- An example of a binding agent is Poly vinylpyrrolidone.
- the polymers of the therapeutic agent layer may be the same as or different from the polymer of the mixing layers.
- the polymer can be liquefied by maintaining the material at a temperature that is greater than its melting point, or glass transition temperature,, or by dissolution in a solvent.
- polymers and copolymers can be prepared by methods well known in the art (see, for example, Rempp and Merril: Polymer Synthesis, 1998, John Wiley and Sons) in or can be used as purchased from Alkermes, in Cambridge, MA or Birmingham Polymer Inc., in Birmingham, Alabama.
- the preferred polymer for use in the therapeutic layer of the present invention is poly vinylpyrrolidone (PVP).
- PVP poly vinylpyrrolidone
- Some drugs that are useful in the present invention are low molecular weight synthetic oligonucleotides and polypeptides, such as 2- chlorodeoxyadenosine, restinase, or restin NG.
- the amount of the drag that is present in the device, and that is required to achieve a therapeutic effect depends on many factors, such as the minimum necessary dosage of the particular drag, the condition to be treated, the chosen location of the inserted device, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
- the mixing layers of the present invention are comprised of a bioresorbable matrix and optionally contain additional additives, therapeutic agents, activating agents, deactivating agents, and the like as described in U.S. patent application serial number 10/253,020.
- the mixing layer may also be comprised of pharmaceutically acceptable lipids or lipid derivatives, which are well known in the art and include but are not limited to fatty acids, fatty acid esters, lysolipids, phosphocholmes, (Avanti Polar Lipids, Alabaster, Ala.), including l-alkyl-2-acetoyl-sn-glycero 3- phosphocholines, and l-alkyl-2-hydroxy-sn-glycero 3 -phosphocholmes; phosphatidylcholine with both saturated and unsaturated lipids, including dioleoylphosphatidylcholine; dimyristoyl-phosphatidylcholine; dipentadecanoyl
- the molar ratio of cationic lipid to non-cationic lipid may be from about 1:2 to about 1:10, with a ratio of from about 1:1 to about 1:2.5 being preferred. Even more preferably, the molar ratio of cationic lipid to non-cationic lipid may be about 1:1. [0072] These lipid materials are well known in the art and can be used as purchased from Avanti, Burnaby, B.C. Canada.
- the preferred lipids for use in the present invention are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, sphingomyelin as well as synthetic phospholipids such as dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, distearoyl phosphatidyl- glycerol, dipalmitoyl phosphatidylglycerol, dimyristoyl phosphatidylserine, distearoyl phosphatidylserine and dipalmitoyl phosphatidylserine.
- the rate at which the bioresorbable matrix resorbs is determined by the choice of lipid, the molecular weight, and the ratio of the chosen materials.
- the mixing layer can resorb by either chemical mechanisms such as chemical interactions, dissolution in water, hydrolysis, or reaction with enzymes, or by physical erosion mechanisms.
- the therapeutic agent that is first incorporated in the therapeutic agent layer is ultimately found throughout the therapeutic agent layer and the mixing layers.
- Each layer is introduced into the holes of the device while in a liquified state and then is allowed to solidify.
- a layer previously solidified within the wells is partially liquefied again when a new liquified layer is introduced on top of the existing solid layer. This allows for the materials of these two layers to mix.
- the concentration of a therapeutic agent in a later applied layer is going to be smaller than the concentration of therapeutic agent in the previously formed layers. This layer method allows for a concentration gradient of therapeutic agent to be formed in the layers within the medical device.
- the mixing layer and the therapeutic agent layer, into which the therapeutic agent is homogeneously or heterogeneously dispersed may each be a homogeneous or heterogeneous mixture.
- the polymers of the mixing layer and the polymers of the therapeutic agent layer are mutually miscible, then the material contained within the holes of the implantable medical device will be a solid solution, or a one phase mixture, comprising each of these polymers.
- the type of two-phase mixture is determined by judicious choice of polymer for each layer, and the percentage of each polymer that dissolves in the solvent used to introduce the mixing layer(s).
- Examples of polymer systems that can form a multi-phase homogeneous mixture include but are not limited to 1) 50% by volume of polylactide and 50% by volume of poly vinylpyrrolidone 2) Poly(lactide-co-glycolide) and polyethylene oxide, and 3) poly DL-lactide and polyethylene oxide.
- the distribution of the therapeutic agent, and thus the kinetic release profile, may be controlled by the selection of the molecular weight of the polymer, the solubility of the polymer and the volume percentage of each of the polymers used within the mixing and the therapeutic agent layers.
- Any of the specific polymers or chemicals listed as a useful matrix material for the mixing layer may also be used in the therapeutic agent layer as a binder and vise- versa.
- the material chosen as a binding agent in therapeutic agent layer has different physical properties than the material used as the matrix in the mixing layers. This may be accomplished by using two different chemicals or polymers.
- the same type of polymer maybe used as long as the physical properties, such as solubility, or hydrophobicity, hydrophilicity or melting point or glass transition temperature can be altered by changing the polymers molecular weight or by adding additional components or additives, such as co-polymers, elasticizers, plasticizers and the like.
- the therapeutic agent which can be heterogeneously or homogeneously dispersed in the therapeutic agent layer and/or the mixing layer, can be a drug, or a drug formulated into a microcapsule, niosome, liposome, microbubble, microsphere, or the like.
- the mixing layer may contain more than one therapeutic agent.
- the medical devices of the present invention can also be medical devices of other shapes useful for site-specific and time-release delivery of drugs to the body and other organs and tissues.
- the drags may be delivered to the vasculature including the coronary and peripheral vessels for a variety of therapies, and to other lumens in the body including the esophagus, urethera, and the bile duct.
- the drugs may increase lumen diameter, create occlusions, or deliver the drug for other reasons.
- NMP N-methylpyrrolidone
- PLGA poly(lactide-co-glycolide)
- lactide:glycolide::85:15 (M v > 100,000 Daltons) 7% wt.
- a suitable organic solvent such as DMSO, NMP, or DMAC 93 % wt.
- the stent is removed from release solution in one vial and placed into fresh solution in the next vial to generate a series of samples containing varying amounts of drug eluted from the stent.
- the amount of drag in a given release solution sample is determined by High Pressure Liquid Chromatography (HPLC). The following conditions are used: Analysis Column: Sym. C 18 (5 ⁇ , 3.9 x 150 mm, Waters Corp., MA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04749514A EP1608415B1 (en) | 2003-03-28 | 2004-03-29 | Therapeutic agent delivery device with controlled therapeutic agent release rates |
CA2520446A CA2520446C (en) | 2003-03-28 | 2004-03-29 | Therapeutic agent delivery device with controlled therapeutic agent release rates |
AU2004226335A AU2004226335A1 (en) | 2003-03-28 | 2004-03-29 | Therapeutic agent delivery device with controlled therapeutic agent release rates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/402,893 | 2003-03-28 | ||
US10/402,893 US7056338B2 (en) | 2003-03-28 | 2003-03-28 | Therapeutic agent delivery device with controlled therapeutic agent release rates |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004087011A2 true WO2004087011A2 (en) | 2004-10-14 |
WO2004087011A3 WO2004087011A3 (en) | 2004-12-16 |
Family
ID=32989838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/009652 WO2004087011A2 (en) | 2003-03-28 | 2004-03-29 | Therapeutic agent delivery device with controlled therapeutic agent release rates |
Country Status (5)
Country | Link |
---|---|
US (3) | US7056338B2 (en) |
EP (2) | EP2289572B1 (en) |
AU (1) | AU2004226335A1 (en) |
CA (1) | CA2520446C (en) |
WO (1) | WO2004087011A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1628597A2 (en) * | 2003-05-28 | 2006-03-01 | Conor Medsystems, Inc. | Methods of delivering anti-restenotic agents from a stent |
DE102006029247A1 (en) * | 2006-06-26 | 2007-12-27 | Biotronik Vi Patent Ag | Implant with a coating comprises one or more components such as cholesterol or cholesterol ester |
JP2010528780A (en) * | 2007-06-05 | 2010-08-26 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | Implantable medical devices for local and local treatment |
CN111246896A (en) * | 2018-01-09 | 2020-06-05 | 上海微特生物技术有限公司 | Degradable blood vessel stent capable of avoiding late restenosis |
Families Citing this family (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU716005B2 (en) | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
US7341598B2 (en) | 1999-01-13 | 2008-03-11 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US7179289B2 (en) * | 1998-03-30 | 2007-02-20 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US7208011B2 (en) * | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US7713297B2 (en) | 1998-04-11 | 2010-05-11 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US6290673B1 (en) | 1999-05-20 | 2001-09-18 | Conor Medsystems, Inc. | Expandable medical device delivery system and method |
EP1229901B1 (en) * | 1999-11-17 | 2009-03-18 | Boston Scientific Limited | Microfabricated devices for the delivery of molecules into a carrier fluid |
EP1132058A1 (en) | 2000-03-06 | 2001-09-12 | Advanced Laser Applications Holding S.A. | Intravascular prothesis |
US7419678B2 (en) * | 2000-05-12 | 2008-09-02 | Cordis Corporation | Coated medical devices for the prevention and treatment of vascular disease |
EP1582180B1 (en) * | 2000-10-16 | 2008-02-27 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
US20100036502A1 (en) * | 2008-08-07 | 2010-02-11 | Exogenesis Corporation | Medical device for bone implant and method for producing such device |
US7727221B2 (en) | 2001-06-27 | 2010-06-01 | Cardiac Pacemakers Inc. | Method and device for electrochemical formation of therapeutic species in vivo |
US7056338B2 (en) * | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
US7842083B2 (en) | 2001-08-20 | 2010-11-30 | Innovational Holdings, Llc. | Expandable medical device with improved spatial distribution |
WO2003048665A1 (en) | 2001-12-03 | 2003-06-12 | Massachusetts Institute Of Technology | Microscale lyophilization and drying methods for the stabilization of molecules |
AU2003228890A1 (en) * | 2002-05-08 | 2003-11-11 | Abbott Laboratories | Endoprosthesis having foot extensions |
US20040033251A1 (en) * | 2002-08-13 | 2004-02-19 | Medtronic, Inc. | Active agent delivery system including a polyurethane, medical device, and method |
AU2003265446A1 (en) * | 2002-08-13 | 2004-02-25 | Medtronic, Inc. | Active agent delivery system including a hydrophilic polymer, medical device, and method |
DE60333566D1 (en) * | 2002-08-13 | 2010-09-09 | Medtronic Inc | MEDICAL DEVICE WITH IMPROVED LIABILITY BETWEEN A POLYMERIC TOUCH AND A SUBSTRATE |
AU2003258209A1 (en) * | 2002-08-13 | 2004-02-25 | Medtronic, Inc. | Active agent delivery systems, medical devices, and methods |
CA2499594A1 (en) * | 2002-09-20 | 2004-04-01 | Conor Medsystems, Inc. | Expandable medical device with openings for delivery of multiple beneficial agents |
US7758636B2 (en) * | 2002-09-20 | 2010-07-20 | Innovational Holdings Llc | Expandable medical device with openings for delivery of multiple beneficial agents |
US20040143321A1 (en) * | 2002-11-08 | 2004-07-22 | Conor Medsystems, Inc. | Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor |
US7169178B1 (en) * | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
US20040202692A1 (en) * | 2003-03-28 | 2004-10-14 | Conor Medsystems, Inc. | Implantable medical device and method for in situ selective modulation of agent delivery |
US20050010170A1 (en) * | 2004-02-11 | 2005-01-13 | Shanley John F | Implantable medical device with beneficial agent concentration gradient |
ATE526038T1 (en) | 2003-03-28 | 2011-10-15 | Innovational Holdings Llc | IMPLANTABLE MEDICAL DEVICE WITH CONTINUOUS MEDIUM CONCENTRATION DISTANCE |
US8048146B2 (en) * | 2003-05-06 | 2011-11-01 | Abbott Laboratories | Endoprosthesis having foot extensions |
US7625401B2 (en) * | 2003-05-06 | 2009-12-01 | Abbott Laboratories | Endoprosthesis having foot extensions |
CA2535345A1 (en) * | 2003-08-13 | 2005-03-03 | Medtronic, Inc. | Active agent delivery systems including a miscible polymer blend, medical devices, and methods |
US20050100577A1 (en) * | 2003-11-10 | 2005-05-12 | Parker Theodore L. | Expandable medical device with beneficial agent matrix formed by a multi solvent system |
US20050182390A1 (en) * | 2004-02-13 | 2005-08-18 | Conor Medsystems, Inc. | Implantable drug delivery device including wire filaments |
US8137397B2 (en) * | 2004-02-26 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical devices |
WO2005122959A2 (en) | 2004-06-08 | 2005-12-29 | Advanced Stent Technologies, Inc. | Stent with protruding branch portion for bifurcated vessels |
WO2006078320A2 (en) * | 2004-08-04 | 2006-07-27 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
EP1799151A4 (en) * | 2004-09-15 | 2014-09-17 | Conor Medsystems Inc | Bifurcation stent with crushable end and method for delivery of a stent to a bifurcation |
EP1853250B1 (en) * | 2005-02-18 | 2011-11-02 | Abraxis BioScience, LLC | Combinations and modes of administration of therapeutic agents and combination therapy |
US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US9060820B2 (en) | 2005-05-18 | 2015-06-23 | Sonoma Orthopedic Products, Inc. | Segmented intramedullary fracture fixation devices and methods |
US8961516B2 (en) | 2005-05-18 | 2015-02-24 | Sonoma Orthopedic Products, Inc. | Straight intramedullary fracture fixation devices and methods |
CA2611117C (en) * | 2005-06-06 | 2015-03-31 | Innovational Holdings Llc | Implantable medical device with openings for delivery of beneficial agents with combination release kinetics |
US9248034B2 (en) | 2005-08-23 | 2016-02-02 | Advanced Cardiovascular Systems, Inc. | Controlled disintegrating implantable medical devices |
US20070196423A1 (en) * | 2005-11-21 | 2007-08-23 | Med Institute, Inc. | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent |
US10029034B2 (en) * | 2005-12-15 | 2018-07-24 | CARDINAL HEALTH SWITZERLAND 515 GmbH | Drug-eluting articles with improved drug release profiles |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8092819B2 (en) * | 2006-01-27 | 2012-01-10 | Cook Medical Technologies LLC. | Implantable medical device coated with a bioactive agent |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US20070224235A1 (en) | 2006-03-24 | 2007-09-27 | Barron Tenney | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US20080051335A1 (en) * | 2006-05-02 | 2008-02-28 | Kleiner Lothar W | Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
JP2009542359A (en) | 2006-06-29 | 2009-12-03 | ボストン サイエンティフィック リミテッド | Medical device with selective covering |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
US20080085293A1 (en) * | 2006-08-22 | 2008-04-10 | Jenchen Yang | Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor |
EP2068757B1 (en) | 2006-09-14 | 2011-05-11 | Boston Scientific Limited | Medical devices with drug-eluting coating |
JP2010503491A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Bioerodible endoprosthesis with biologically stable inorganic layers |
EP2068782B1 (en) | 2006-09-15 | 2011-07-27 | Boston Scientific Limited | Bioerodible endoprostheses |
EP2081616B1 (en) | 2006-09-15 | 2017-11-01 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
CA2663220A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
EP2073765A2 (en) * | 2006-09-25 | 2009-07-01 | Boston Scientific Limited | Injection of therapeutic into porous regions of a medical device |
US7951191B2 (en) | 2006-10-10 | 2011-05-31 | Boston Scientific Scimed, Inc. | Bifurcated stent with entire circumferential petal |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
AU2007323566A1 (en) | 2006-11-22 | 2008-05-29 | Sonoma Orthopedic Products, Inc. | Fracture fixation device, tools and methods |
DE602007010669D1 (en) | 2006-12-28 | 2010-12-30 | Boston Scient Ltd | HREN FOR THIS |
US8221496B2 (en) * | 2007-02-01 | 2012-07-17 | Cordis Corporation | Antithrombotic and anti-restenotic drug eluting stent |
US8070797B2 (en) * | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US8067054B2 (en) * | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
US20090018542A1 (en) * | 2007-07-11 | 2009-01-15 | Sonoma Orthopedic Products,Inc. | Fracture fixation devices, systems and methods incorporating a membrane |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
JP2010533563A (en) | 2007-07-19 | 2010-10-28 | ボストン サイエンティフィック リミテッド | Endoprosthesis with adsorption inhibiting surface |
US8070798B2 (en) * | 2007-07-20 | 2011-12-06 | Josiah Wilcox | Drug eluting medical device and method |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
US8221822B2 (en) | 2007-07-31 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
JP2010535541A (en) | 2007-08-03 | 2010-11-25 | ボストン サイエンティフィック リミテッド | Coating for medical devices with large surface area |
US7959669B2 (en) | 2007-09-12 | 2011-06-14 | Boston Scientific Scimed, Inc. | Bifurcated stent with open ended side branch support |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7833266B2 (en) | 2007-11-28 | 2010-11-16 | Boston Scientific Scimed, Inc. | Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment |
WO2009085952A1 (en) | 2007-12-20 | 2009-07-09 | Brookwood Pharmaceuticals, Inc. | Process for preparing microparticles having a low residual solvent volume |
US8277501B2 (en) | 2007-12-21 | 2012-10-02 | Boston Scientific Scimed, Inc. | Bi-stable bifurcated stent petal geometry |
US8057876B2 (en) | 2008-02-25 | 2011-11-15 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent with layers having different degradation rates |
US8920491B2 (en) | 2008-04-22 | 2014-12-30 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
US8932346B2 (en) | 2008-04-24 | 2015-01-13 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8932340B2 (en) | 2008-05-29 | 2015-01-13 | Boston Scientific Scimed, Inc. | Bifurcated stent and delivery system |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8449603B2 (en) | 2008-06-18 | 2013-05-28 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US20090319026A1 (en) * | 2008-06-20 | 2009-12-24 | Boston Scientific Scimed, Inc. | Composite Stent with Reservoirs for Drug Delivery and Methods of Manufacturing |
US9039756B2 (en) | 2008-07-21 | 2015-05-26 | Jenesis Surgical, Llc | Repositionable endoluminal support structure and its applications |
AU2009274131B2 (en) | 2008-07-21 | 2015-06-04 | Jennifer K. White | Repositionable endoluminal support structure and its applications |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
WO2010017456A2 (en) * | 2008-08-07 | 2010-02-11 | Exogenesis Corporation | Drug delivery system and method of munufacturing thereof |
US9616205B2 (en) | 2008-08-13 | 2017-04-11 | Smed-Ta/Td, Llc | Drug delivery implants |
US10842645B2 (en) | 2008-08-13 | 2020-11-24 | Smed-Ta/Td, Llc | Orthopaedic implant with porous structural member |
JP5774989B2 (en) | 2008-08-13 | 2015-09-09 | スメド−ティーエイ/ティーディー・エルエルシー | Orthopedic screw |
US9700431B2 (en) | 2008-08-13 | 2017-07-11 | Smed-Ta/Td, Llc | Orthopaedic implant with porous structural member |
WO2010019781A1 (en) | 2008-08-13 | 2010-02-18 | Smed-Ta/Td, Llc | Drug delivery implants |
US8642063B2 (en) | 2008-08-22 | 2014-02-04 | Cook Medical Technologies Llc | Implantable medical device coatings with biodegradable elastomer and releasable taxane agent |
ES2686906T3 (en) * | 2008-08-29 | 2018-10-22 | Smed-Ta/Td, Llc | Orthopedic implant |
EP2341857A2 (en) | 2008-09-26 | 2011-07-13 | Sonoma Orthopedic Products, Inc. | Bone fixation device, tools and methods |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
EP2346421A1 (en) * | 2008-10-15 | 2011-07-27 | Bioshape Solutions Inc. | Device and method for delivery of therapeutic agents via internal implants |
US9642658B2 (en) * | 2008-10-15 | 2017-05-09 | Orthoclip Llc | Device and method for delivery of therapeutic agents via internal implants |
GB0818933D0 (en) * | 2008-10-16 | 2008-11-19 | Depuy Int Ltd | An implantable medical device |
ES2645692T3 (en) | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Rapamycin microcapsules and their use for cancer treatment |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
US7819914B2 (en) * | 2008-12-16 | 2010-10-26 | Cordis Corporation | Adhesion promoting primer for coated surfaces |
WO2010101901A2 (en) | 2009-03-02 | 2010-09-10 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US9592043B2 (en) * | 2009-03-31 | 2017-03-14 | Covidien Lp | Multizone implants |
US20100249944A1 (en) * | 2009-03-31 | 2010-09-30 | Thomas Jonathan D | Multizone Implants |
US20100249832A1 (en) * | 2009-03-31 | 2010-09-30 | Joshua Stopek | Multizone Implants |
US20100249854A1 (en) * | 2009-03-31 | 2010-09-30 | Thomas Jonathan D | Multizone Implants |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
US20100292777A1 (en) * | 2009-05-13 | 2010-11-18 | Boston Scientific Scimed, Inc. | Stent |
US20110137407A1 (en) * | 2009-07-09 | 2011-06-09 | Thai Minh Nguyen | Bare metal stent with drug eluting reservoirs |
FR2949688B1 (en) * | 2009-09-04 | 2012-08-24 | Sofradim Production | FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER |
KR20120107070A (en) * | 2009-09-22 | 2012-09-28 | 에보닉 데구사 코포레이션 | Implant devices having varying bioactive agent loading configurations |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
US9216240B2 (en) * | 2010-02-03 | 2015-12-22 | Covidien Lp | Differential loading of drug-eluting medical devices |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
JP6242213B2 (en) | 2010-03-29 | 2017-12-06 | アブラクシス バイオサイエンス, エルエルシー | Methods for improving the effectiveness of drug delivery and therapeutic agents |
KR20130028728A (en) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | Methods of treating cancer |
KR20180049180A (en) | 2010-06-04 | 2018-05-10 | 아브락시스 바이오사이언스, 엘엘씨 | Methods of treatment of pancreatic cancer |
EP2399619B1 (en) * | 2010-06-25 | 2015-08-05 | Biotronik AG | Implant and Method for Manufacturing Same |
US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
CN117796970A (en) | 2013-03-13 | 2024-04-02 | 爱德华兹生命科学卡迪尔克有限责任公司 | Articulating commissure stent and method |
WO2014144188A1 (en) * | 2013-03-15 | 2014-09-18 | Cook Medical Technologies Llc | Drug eluting graft constructs and methods |
WO2014165829A2 (en) * | 2013-04-05 | 2014-10-09 | Igdrasol | Nanoparticle formulations |
IN2013MU02532A (en) | 2013-07-31 | 2015-06-26 | Sahajanand Medical Technologies Pvt Ltd | |
CN116158889A (en) | 2013-11-11 | 2023-05-26 | 爱德华兹生命科学卡迪尔克有限责任公司 | System and method for manufacturing a stent frame |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
US9770278B2 (en) | 2014-01-17 | 2017-09-26 | Arthrex, Inc. | Dual tip guide wire |
US9814499B2 (en) | 2014-09-30 | 2017-11-14 | Arthrex, Inc. | Intramedullary fracture fixation devices and methods |
EP3527194B1 (en) * | 2016-10-17 | 2024-02-14 | Pola Chemical Industries, Inc. | Composite particles including anionic polymer and cationic polymer or peptide, and method for producing composite particles |
CN109381751B (en) * | 2017-08-08 | 2022-01-28 | 上海微创医疗器械(集团)有限公司 | Degradable metal stent and preparation method thereof |
CN111759552A (en) | 2020-07-06 | 2020-10-13 | 苏州莱诺医疗器械有限公司 | Absorbable stent system |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0875218A2 (en) * | 1997-04-15 | 1998-11-04 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
WO2001017577A1 (en) * | 1999-09-03 | 2001-03-15 | Advanced Cardiovascular Systems, Inc. | A porous prosthesis and a method of depositing substances into the pores |
US20010027340A1 (en) * | 1997-04-18 | 2001-10-04 | Carol Wright | Stent with therapeutically active dosage of rapamycin coated thereon |
DE20200220U1 (en) * | 2002-01-08 | 2002-03-21 | Translumina Gmbh | stent |
US20020082680A1 (en) * | 2000-10-16 | 2002-06-27 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
Family Cites Families (203)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US624501A (en) * | 1899-05-09 | Thill-coupling | ||
US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US5876419A (en) * | 1976-10-02 | 1999-03-02 | Navius Corporation | Stent and method for making a stent |
US5643314A (en) | 1995-11-13 | 1997-07-01 | Navius Corporation | Self-expanding stent |
JPS6037735B2 (en) * | 1978-10-18 | 1985-08-28 | 住友電気工業株式会社 | Artificial blood vessel |
US4300244A (en) | 1979-09-19 | 1981-11-17 | Carbomedics, Inc. | Cardiovascular grafts |
US4531936A (en) | 1981-01-29 | 1985-07-30 | Gordon Robert T | Device and method for the selective delivery of drugs to the myocardium |
US5441745A (en) | 1982-03-30 | 1995-08-15 | Vestar, Inc. | Method of delivering micellular particles encapsulating chemotherapeutic agents to tumors in a body |
US4542025A (en) | 1982-07-29 | 1985-09-17 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4834755A (en) | 1983-04-04 | 1989-05-30 | Pfizer Hospital Products Group, Inc. | Triaxially-braided fabric prosthesis |
US4580568A (en) | 1984-10-01 | 1986-04-08 | Cook, Incorporated | Percutaneous endovascular stent and method for insertion thereof |
US4824436A (en) | 1985-04-09 | 1989-04-25 | Harvey Wolinsky | Method for the prevention of restenosis |
US4650466A (en) | 1985-11-01 | 1987-03-17 | Angiobrade Partners | Angioplasty device |
US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4955878A (en) | 1986-04-04 | 1990-09-11 | Biotechnology, Inc. | Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures |
JPH0763489B2 (en) | 1986-10-31 | 1995-07-12 | 宇部興産株式会社 | Medical tube |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US5059211A (en) | 1987-06-25 | 1991-10-22 | Duke University | Absorbable vascular stent |
US4969458A (en) | 1987-07-06 | 1990-11-13 | Medtronic, Inc. | Intracoronary stent and method of simultaneous angioplasty and stent implant |
US5460817A (en) | 1988-01-19 | 1995-10-24 | Allied Colloids Ltd. | Particulate composition comprising a core of matrix polymer with active ingredient distributed therein |
US5157049A (en) | 1988-03-07 | 1992-10-20 | The United States Of America As Represented By The Department Of Health & Human Services | Method of treating cancers sensitive to treatment with water soluble derivatives of taxol |
EP0430968B1 (en) | 1988-05-02 | 1996-11-20 | PHANOS TECHNOLOGIES, Inc. | Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles |
US4989601A (en) | 1988-05-02 | 1991-02-05 | Medical Engineering & Development Institute, Inc. | Method, apparatus, and substance for treating tissue having neoplastic cells |
US5213580A (en) | 1988-08-24 | 1993-05-25 | Endoluminal Therapeutics, Inc. | Biodegradable polymeric endoluminal sealing process |
US5019090A (en) | 1988-09-01 | 1991-05-28 | Corvita Corporation | Radially expandable endoprosthesis and the like |
US5053048A (en) | 1988-09-22 | 1991-10-01 | Cordis Corporation | Thromboresistant coating |
CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
LU87410A1 (en) | 1988-12-20 | 1990-07-10 | Cird | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING POLYMERIC OR FATTY BODY MICROSPHERES CHARGED WITH AT LEAST ONE ACTIVE PRODUCT |
CH678393A5 (en) | 1989-01-26 | 1991-09-13 | Ulrich Prof Dr Med Sigwart | |
US5078726A (en) | 1989-02-01 | 1992-01-07 | Kreamer Jeffry W | Graft stent and method of repairing blood vessels |
JPH02207940A (en) | 1989-02-06 | 1990-08-17 | Olympus Optical Co Ltd | Molding material of phosphate system |
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US4990155A (en) | 1989-05-19 | 1991-02-05 | Wilkoff Howard M | Surgical stent method and apparatus |
US4994071A (en) | 1989-05-22 | 1991-02-19 | Cordis Corporation | Bifurcating stent apparatus and method |
US5171262A (en) | 1989-06-15 | 1992-12-15 | Cordis Corporation | Non-woven endoprosthesis |
US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
US5176617A (en) | 1989-12-11 | 1993-01-05 | Medical Innovative Technologies R & D Limited Partnership | Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct |
US5059166A (en) | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
US5049132A (en) | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
DE69108423T2 (en) | 1990-02-08 | 1995-07-27 | Howmedica | Inflatable dilator. |
US5545208A (en) | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5344426A (en) | 1990-04-25 | 1994-09-06 | Advanced Cardiovascular Systems, Inc. | Method and system for stent delivery |
US5242399A (en) | 1990-04-25 | 1993-09-07 | Advanced Cardiovascular Systems, Inc. | Method and system for stent delivery |
US5290271A (en) * | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
US5092841A (en) | 1990-05-17 | 1992-03-03 | Wayne State University | Method for treating an arterial wall injured during angioplasty |
WO1991017724A1 (en) | 1990-05-17 | 1991-11-28 | Harbor Medical Devices, Inc. | Medical device polymer |
US5407683A (en) | 1990-06-01 | 1995-04-18 | Research Corporation Technologies, Inc. | Pharmaceutical solutions and emulsions containing taxol |
AU8074591A (en) | 1990-06-15 | 1992-01-07 | Cortrak Medical, Inc. | Drug delivery apparatus and method |
WO1992015286A1 (en) * | 1991-02-27 | 1992-09-17 | Nova Pharmaceutical Corporation | Anti-infective and anti-inflammatory releasing systems for medical devices |
US5171217A (en) | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
US5197978B1 (en) | 1991-04-26 | 1996-05-28 | Advanced Coronary Tech | Removable heat-recoverable tissue supporting device |
FR2678833B1 (en) | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | NEW PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE TAXANE CLASS. |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) * | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5500013A (en) * | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5464450A (en) | 1991-10-04 | 1995-11-07 | Scimed Lifesystems Inc. | Biodegradable drug delivery vascular stent |
WO1993006792A1 (en) | 1991-10-04 | 1993-04-15 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
CA2380683C (en) * | 1991-10-28 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Expandable stents and method for making same |
FR2683449A1 (en) | 1991-11-08 | 1993-05-14 | Cardon Alain | ENDOPROTHESIS FOR TRANSLUMINAL IMPLANTATION. |
US5270047A (en) | 1991-11-21 | 1993-12-14 | Kauffman Raymond F | Local delivery of dipyridamole for the treatment of proliferative diseases |
US5260002A (en) | 1991-12-23 | 1993-11-09 | Vanderbilt University | Method and apparatus for producing uniform polymeric spheres |
US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
CA2087132A1 (en) | 1992-01-31 | 1993-08-01 | Michael S. Williams | Stent capable of attachment within a body lumen |
US5282823A (en) | 1992-03-19 | 1994-02-01 | Medtronic, Inc. | Intravascular radially expandable stent |
MX9301821A (en) | 1992-03-30 | 1994-03-31 | Alza Corp | BIODEGRADABLE POLYMERICAL MATRIX SYSTEM DEGRADATION REGULATOR AND METHOD OF TREATMENT OF THE SAME. |
US5383928A (en) | 1992-06-10 | 1995-01-24 | Emory University | Stent sheath for local drug delivery |
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
DE4222380A1 (en) * | 1992-07-08 | 1994-01-13 | Ernst Peter Prof Dr M Strecker | Endoprosthesis implantable percutaneously in a patient's body |
KR940003548U (en) | 1992-08-14 | 1994-02-21 | 김형술 | Laundry dryer |
US5342621A (en) | 1992-09-15 | 1994-08-30 | Advanced Cardiovascular Systems, Inc. | Antithrombogenic surface |
US5578075B1 (en) | 1992-11-04 | 2000-02-08 | Daynke Res Inc | Minimally invasive bioactivated endoprosthesis for vessel repair |
US5342348A (en) | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
KR0147482B1 (en) | 1993-01-19 | 1998-08-01 | 알렌 제이. 스피겔 | Clad composite stent |
US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US5981568A (en) * | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US5441515A (en) | 1993-04-23 | 1995-08-15 | Advanced Cardiovascular Systems, Inc. | Ratcheting stent |
EP0621015B1 (en) | 1993-04-23 | 1998-03-18 | Schneider (Europe) Ag | Stent with a covering layer of elastic material and method for applying the layer on the stent |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
ATE406909T1 (en) | 1993-05-13 | 2008-09-15 | Poniard Pharmaceuticals Inc | PREVENTION AND TREATMENT OF PATHOLOGIES ASSOCIATED WITH ABNORMAL PROLIFERATION OF SMOOTH MUSCLE CELLS |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US20030203976A1 (en) * | 1993-07-19 | 2003-10-30 | William L. Hunter | Anti-angiogenic compositions and methods of use |
DK0797988T3 (en) * | 1993-07-19 | 2009-05-11 | Univ British Columbia | Anti-angiogenic compositions and methods for their use |
EP1118325B2 (en) | 1993-07-29 | 2010-01-06 | The United States of America, represented by the Secretary, Department of Health and Human Services | Use of Paclitaxel and its derivatives in the manufacture of a medicament for treating restenosis. |
US5380299A (en) | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
US5457113A (en) | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5443497A (en) | 1993-11-22 | 1995-08-22 | The Johns Hopkins University | Percutaneous prosthetic by-pass graft and method of use |
US5556413A (en) | 1994-03-11 | 1996-09-17 | Advanced Cardiovascular Systems, Inc. | Coiled stent with locking ends |
US5449373A (en) | 1994-03-17 | 1995-09-12 | Medinol Ltd. | Articulated stent |
US5660873A (en) | 1994-09-09 | 1997-08-26 | Bioseal, Limited Liability Corporaton | Coating intraluminal stents |
US5891108A (en) * | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
US5545210A (en) | 1994-09-22 | 1996-08-13 | Advanced Coronary Technology, Inc. | Method of implanting a permanent shape memory alloy stent |
US5707385A (en) | 1994-11-16 | 1998-01-13 | Advanced Cardiovascular Systems, Inc. | Drug loaded elastic membrane and method for delivery |
CA2301351C (en) * | 1994-11-28 | 2002-01-22 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for direct laser cutting of metal stents |
US5665591A (en) | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US5575771A (en) | 1995-04-24 | 1996-11-19 | Walinsky; Paul | Balloon catheter with external guidewire |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US6774278B1 (en) * | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
AU716005B2 (en) * | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
US5607442A (en) | 1995-11-13 | 1997-03-04 | Isostent, Inc. | Stent with improved radiopacity and appearance characteristics |
US5741293A (en) * | 1995-11-28 | 1998-04-21 | Wijay; Bandula | Locking stent |
US6017363A (en) * | 1997-09-22 | 2000-01-25 | Cordis Corporation | Bifurcated axially flexible stent |
US6334871B1 (en) * | 1996-03-13 | 2002-01-01 | Medtronic, Inc. | Radiopaque stent markers |
US5725548A (en) | 1996-04-08 | 1998-03-10 | Iowa India Investments Company Limited | Self-locking stent and method for its production |
US5713949A (en) | 1996-08-06 | 1998-02-03 | Jayaraman; Swaminathan | Microporous covered stents and method of coating |
US6783543B2 (en) * | 2000-06-05 | 2004-08-31 | Scimed Life Systems, Inc. | Intravascular stent with increasing coating retaining capacity |
US5617878A (en) | 1996-05-31 | 1997-04-08 | Taheri; Syde A. | Stent and method for treatment of aortic occlusive disease |
US5697971A (en) | 1996-06-11 | 1997-12-16 | Fischell; Robert E. | Multi-cell stent with cells having differing characteristics |
US6174326B1 (en) * | 1996-09-25 | 2001-01-16 | Terumo Kabushiki Kaisha | Radiopaque, antithrombogenic stent and method for its production |
US5868781A (en) * | 1996-10-22 | 1999-02-09 | Scimed Life Systems, Inc. | Locking stent |
ZA9710342B (en) * | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US5733330A (en) | 1997-01-13 | 1998-03-31 | Advanced Cardiovascular Systems, Inc. | Balloon-expandable, crush-resistant locking stent |
US6033433A (en) * | 1997-04-25 | 2000-03-07 | Scimed Life Systems, Inc. | Stent configurations including spirals |
US5855600A (en) * | 1997-08-01 | 1999-01-05 | Inflow Dynamics Inc. | Flexible implantable stent with composite design |
US6042606A (en) * | 1997-09-29 | 2000-03-28 | Cook Incorporated | Radially expandable non-axially contracting surgical stent |
US6030414A (en) * | 1997-11-13 | 2000-02-29 | Taheri; Syde A. | Variable stent and method for treatment of arterial disease |
US6241762B1 (en) * | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US7208011B2 (en) * | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
US6019789A (en) * | 1998-04-01 | 2000-02-01 | Quanam Medical Corporation | Expandable unit cell and intraluminal stent |
US6206916B1 (en) * | 1998-04-15 | 2001-03-27 | Joseph G. Furst | Coated intraluminal graft |
US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
US6423345B2 (en) * | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
US20020038146A1 (en) * | 1998-07-29 | 2002-03-28 | Ulf Harry | Expandable stent with relief cuts for carrying medicines and other materials |
WO2000010622A1 (en) * | 1998-08-20 | 2000-03-02 | Cook Incorporated | Coated implantable medical device |
US7662409B2 (en) * | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US6206915B1 (en) * | 1998-09-29 | 2001-03-27 | Medtronic Ave, Inc. | Drug storing and metering stent |
US6293967B1 (en) * | 1998-10-29 | 2001-09-25 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US6528121B2 (en) * | 1998-11-19 | 2003-03-04 | Dow Corning Toray Silicone Co., Ltd. | Aqueous treatment agent for wiping paper |
ES2204798T3 (en) * | 1998-12-21 | 2004-05-01 | Lonza Ag | PROCEDURE FOR THE PREPARATION OF 2,5-DIAMINO-4,6-DIHALOGENOPIRIMIDINE. |
US6530950B1 (en) * | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
ATE321803T1 (en) * | 1999-04-16 | 2006-04-15 | Univ Wm Marsh Rice | FUNCTIONALIZED POLYPROPYLENE FUMARATE AND POLYPROPYLENE FUMARATE-CO-ETHYLENE GLYCOL |
US6334807B1 (en) * | 1999-04-30 | 2002-01-01 | International Business Machines Corporation | Chemical mechanical polishing in-situ end point system |
US6245101B1 (en) * | 1999-05-03 | 2001-06-12 | William J. Drasler | Intravascular hinge stent |
US6290673B1 (en) * | 1999-05-20 | 2001-09-18 | Conor Medsystems, Inc. | Expandable medical device delivery system and method |
US6503954B1 (en) * | 2000-03-31 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing actinomycin D and a method of forming the same |
US6379381B1 (en) * | 1999-09-03 | 2002-04-30 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6713119B2 (en) * | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
US6682545B1 (en) * | 1999-10-06 | 2004-01-27 | The Penn State Research Foundation | System and device for preventing restenosis in body vessels |
US6428569B1 (en) * | 1999-11-09 | 2002-08-06 | Scimed Life Systems Inc. | Micro structure stent configurations |
EP1229901B1 (en) * | 1999-11-17 | 2009-03-18 | Boston Scientific Limited | Microfabricated devices for the delivery of molecules into a carrier fluid |
US6375826B1 (en) * | 2000-02-14 | 2002-04-23 | Advanced Cardiovascular Systems, Inc. | Electro-polishing fixture and electrolyte solution for polishing stents and method |
WO2001064344A2 (en) * | 2000-03-02 | 2001-09-07 | Microchips, Inc. | Microfabricated devices for the storage and selective exposure of chemicals and devices |
EP1132058A1 (en) * | 2000-03-06 | 2001-09-12 | Advanced Laser Applications Holding S.A. | Intravascular prothesis |
US20020007215A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007213A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US20020005206A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US20020007214A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
CA2409003C (en) * | 2000-05-16 | 2010-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Process for coating medical devices using super-critical carbon dioxide |
US6673385B1 (en) * | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
US6723373B1 (en) * | 2000-06-16 | 2004-04-20 | Cordis Corporation | Device and process for coating stents |
US6555157B1 (en) * | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
US6548308B2 (en) * | 2000-09-25 | 2003-04-15 | Picoliter Inc. | Focused acoustic energy method and device for generating droplets of immiscible fluids |
US6716444B1 (en) * | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US6863685B2 (en) * | 2001-03-29 | 2005-03-08 | Cordis Corporation | Radiopacity intraluminal medical device |
US6506437B1 (en) * | 2000-10-17 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device having depots formed in a surface thereof |
US10398830B2 (en) * | 2000-11-17 | 2019-09-03 | Vactronix Scientific, Llc | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
WO2002059261A2 (en) * | 2000-12-07 | 2002-08-01 | The Medstar Research Institute | Inhibition of restenosis using a dna-coated stent |
US6545097B2 (en) * | 2000-12-12 | 2003-04-08 | Scimed Life Systems, Inc. | Drug delivery compositions and medical devices containing block copolymer |
US20030033007A1 (en) * | 2000-12-22 | 2003-02-13 | Avantec Vascular Corporation | Methods and devices for delivery of therapeutic capable agents with variable release profile |
US6663662B2 (en) * | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
US6964680B2 (en) * | 2001-02-05 | 2005-11-15 | Conor Medsystems, Inc. | Expandable medical device with tapered hinge |
AU2002254158A1 (en) * | 2001-03-08 | 2002-09-24 | Volcano Therapeutics, Inc. | Medical devices, compositions and methods for treating vulnerable plaque |
US6378988B1 (en) * | 2001-03-19 | 2002-04-30 | Microfab Technologies, Inc. | Cartridge element for micro jet dispensing |
US6712845B2 (en) * | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
US6679980B1 (en) * | 2001-06-13 | 2004-01-20 | Advanced Cardiovascular Systems, Inc. | Apparatus for electropolishing a stent |
US7493162B2 (en) * | 2001-06-15 | 2009-02-17 | Cardiac Pacemakers, Inc. | Pulmonary vein stent for treating atrial fibrillation |
US6656216B1 (en) * | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
US6676987B2 (en) * | 2001-07-02 | 2004-01-13 | Scimed Life Systems, Inc. | Coating a medical appliance with a bubble jet printing head |
US6682771B2 (en) * | 2001-07-02 | 2004-01-27 | Scimed Life Systems, Inc. | Coating dispensing system and method using a solenoid head for coating medical devices |
US20030050687A1 (en) * | 2001-07-03 | 2003-03-13 | Schwade Nathan D. | Biocompatible stents and method of deployment |
DE60120955T3 (en) * | 2001-07-20 | 2015-06-25 | Cid S.P.A. | stent |
US7056338B2 (en) * | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
US7195640B2 (en) * | 2001-09-25 | 2007-03-27 | Cordis Corporation | Coated medical devices for the treatment of vulnerable plaque |
DE10150995A1 (en) * | 2001-10-08 | 2003-04-10 | Biotronik Mess & Therapieg | Implant e.g. a stent, comprises a decomposable substance which allows contact between the cell proliferation inhibitor and the stent surroundings only after a specified time |
US20030077312A1 (en) * | 2001-10-22 | 2003-04-24 | Ascher Schmulewicz | Coated intraluminal stents and reduction of restenosis using same |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
EP1310242A1 (en) * | 2001-11-13 | 2003-05-14 | SORIN BIOMEDICA CARDIO S.p.A. | Carrier and kit for endoluminal delivery of active principles |
US20030181973A1 (en) * | 2002-03-20 | 2003-09-25 | Harvinder Sahota | Reduced restenosis drug containing stents |
US6743463B2 (en) * | 2002-03-28 | 2004-06-01 | Scimed Life Systems, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
EP1348402A1 (en) * | 2002-03-29 | 2003-10-01 | Advanced Laser Applications Holding S.A. | Intraluminal endoprosthesis, radially expandable, perforated for drug delivery |
US20030204239A1 (en) * | 2002-04-26 | 2003-10-30 | Wenda Carlyle | Endovascular stent with a preservative coating |
US20040127976A1 (en) * | 2002-09-20 | 2004-07-01 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
US6702850B1 (en) * | 2002-09-30 | 2004-03-09 | Mediplex Corporation Korea | Multi-coated drug-eluting stent for antithrombosis and antirestenosis |
WO2004043510A1 (en) * | 2002-11-08 | 2004-05-27 | Conor Medsystems, Inc. | Method and apparatus for reducing tissue damage after ischemic injury |
CN1714085A (en) * | 2002-11-15 | 2005-12-28 | 诺瓦提斯公司 | Drug delivery system |
US20050049693A1 (en) * | 2003-08-25 | 2005-03-03 | Medtronic Vascular Inc. | Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease |
US20050055078A1 (en) * | 2003-09-04 | 2005-03-10 | Medtronic Vascular, Inc. | Stent with outer slough coating |
US20050060020A1 (en) * | 2003-09-17 | 2005-03-17 | Scimed Life Systems, Inc. | Covered stent with biologically active material |
US7060319B2 (en) * | 2003-09-24 | 2006-06-13 | Boston Scientific Scimed, Inc. | method for using an ultrasonic nozzle to coat a medical appliance |
US8801692B2 (en) * | 2003-09-24 | 2014-08-12 | Medtronic Vascular, Inc. | Gradient coated stent and method of fabrication |
US7055237B2 (en) * | 2003-09-29 | 2006-06-06 | Medtronic Vascular, Inc. | Method of forming a drug eluting stent |
US20060017834A1 (en) * | 2004-07-23 | 2006-01-26 | Konica Minolta Opto, Inc. | Imaging optical system and imaging lens device |
-
2003
- 2003-03-28 US US10/402,893 patent/US7056338B2/en not_active Expired - Lifetime
-
2004
- 2004-03-29 AU AU2004226335A patent/AU2004226335A1/en not_active Abandoned
- 2004-03-29 CA CA2520446A patent/CA2520446C/en not_active Expired - Fee Related
- 2004-03-29 EP EP10011830.6A patent/EP2289572B1/en not_active Expired - Lifetime
- 2004-03-29 WO PCT/US2004/009652 patent/WO2004087011A2/en active Application Filing
- 2004-03-29 EP EP04749514A patent/EP1608415B1/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,174 patent/US7517362B2/en not_active Expired - Fee Related
-
2005
- 2005-09-13 US US11/226,523 patent/US20060008503A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0875218A2 (en) * | 1997-04-15 | 1998-11-04 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US20010027340A1 (en) * | 1997-04-18 | 2001-10-04 | Carol Wright | Stent with therapeutically active dosage of rapamycin coated thereon |
US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
WO2001017577A1 (en) * | 1999-09-03 | 2001-03-15 | Advanced Cardiovascular Systems, Inc. | A porous prosthesis and a method of depositing substances into the pores |
US20020082680A1 (en) * | 2000-10-16 | 2002-06-27 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
DE20200220U1 (en) * | 2002-01-08 | 2002-03-21 | Translumina Gmbh | stent |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1628597A2 (en) * | 2003-05-28 | 2006-03-01 | Conor Medsystems, Inc. | Methods of delivering anti-restenotic agents from a stent |
EP1628597A4 (en) * | 2003-05-28 | 2008-12-10 | Conor Medsystems Inc | Methods of delivering anti-restenotic agents from a stent |
DE102006029247A1 (en) * | 2006-06-26 | 2007-12-27 | Biotronik Vi Patent Ag | Implant with a coating comprises one or more components such as cholesterol or cholesterol ester |
JP2010528780A (en) * | 2007-06-05 | 2010-08-26 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | Implantable medical devices for local and local treatment |
CN111246896A (en) * | 2018-01-09 | 2020-06-05 | 上海微特生物技术有限公司 | Degradable blood vessel stent capable of avoiding late restenosis |
Also Published As
Publication number | Publication date |
---|---|
US20060008503A1 (en) | 2006-01-12 |
AU2004226335A1 (en) | 2004-10-14 |
US20050058684A1 (en) | 2005-03-17 |
EP1608415A2 (en) | 2005-12-28 |
US7056338B2 (en) | 2006-06-06 |
US7517362B2 (en) | 2009-04-14 |
WO2004087011A3 (en) | 2004-12-16 |
CA2520446C (en) | 2013-12-10 |
EP2289572A2 (en) | 2011-03-02 |
EP1608415B1 (en) | 2013-02-20 |
EP2289572A3 (en) | 2012-04-04 |
US20040193255A1 (en) | 2004-09-30 |
CA2520446A1 (en) | 2004-10-14 |
EP2289572B1 (en) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2289572B1 (en) | Therapeutic agent delivery device with controlled therapeutic agent release rates | |
EP1749544B1 (en) | Therapeutic agent delivery device with protective separating layer | |
US8361537B2 (en) | Expandable medical device with beneficial agent concentration gradient | |
CA2504524C (en) | Method and apparatus for treating vulnerable artherosclerotic plaque | |
CA2528166C (en) | Drug delivery device and method for bi-directional drug delivery | |
EP1768610B1 (en) | Expandable medical device for treating cardiac arrhythmias | |
EP1772122B1 (en) | Expandable medical device for delivery of beneficial agent | |
CA2615143A1 (en) | Expandable medical device with openings for delivery of multiple beneficial agents | |
AU2009240874B2 (en) | Adhesion promoting primer for coated surfaces | |
AU2010200882A1 (en) | Expandable medical device for delivery of beneficial agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2520446 Country of ref document: CA Ref document number: 2004226335 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004749514 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004226335 Country of ref document: AU Date of ref document: 20040329 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004226335 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004749514 Country of ref document: EP |